Amendment: SEC Form SC 13D/A filed by Incyte Corp.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 31)*

Incyte Corporation

(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)

45337C102

(CUSIP number)

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

860 Washington Street, 3^rd Floor

New York, NY 10014

(212) 339-5690

(Name, address and telephone number of person authorized to receive notices and communications)

June 12, 2024

(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

(Continued on the following pages)

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1) Includes 111,414 shares of common stock (“Common Stock”) of Incyte Corporation (the “Issuer”) underlying 111,414 non-qualified options exercisable for Common Stock (“Stock Options”).

(2) Based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, minus 27,866,666 shares of Common Stock purchased by the Issuer in the tender offer that was completed as of the date of this filing and 5,459,183 shares of Common Stock sold by the Funds (as defined below) to the Issuer pursuant to the Stock Purchase Agreement (as defined in Item 4) dated May 12, 2024 plus 111,414 shares of Common Stock underlying 111,414 Stock Options plus 2,505 shares of Common Stock received from vested restricted stock units (each, an “RSU”).

(1) Includes 111,414 shares of Common Stock underlying 111,414 Stock Options.

(2) Based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, minus 27,866,666 shares of Common Stock purchased by the Issuer in the tender offer that was completed as of the date of this filing and 5,459,183 shares of Common Stock sold by the Funds (as defined below) to the Issuer pursuant to the Stock Purchase Agreement (as defined in Item 4) dated May 12, 2024 plus 111,414 shares of Common Stock underlying 111,414 Stock Options plus 2,505 shares of Common Stock received from vested RSUs. 

(1) Includes 111,414 shares of Common Stock underlying 111,414 Stock Options.

(2) Based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, minus 27,866,666 shares of Common Stock purchased by the Issuer in the tender offer that was completed as of the date of this filing and 5,459,183 shares of Common Stock sold by the Funds (as defined below) to the Issuer pursuant to the Stock Purchase Agreement (as defined in Item 4) dated May 12, 2024 plus 111,414 shares of Common Stock underlying 111,414 Stock Options plus 2,505 shares of Common Stock received from vested RSUs.

(1) Includes 111,414 shares of Common Stock underlying 111,414 Stock Options.

(2) Based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, minus 27,866,666 shares of Common Stock purchased by the Issuer in the tender offer that was completed as of the date of this filing and 5,459,183 shares of Common Stock sold by the Funds (as defined below) to the Issuer pursuant to the Stock Purchase Agreement (as defined in Item 4) dated May 12, 2024 plus 111,414 shares of Common Stock underlying 111,414 Stock Options plus 2,505 shares of Common Stock received from vested RSUs.

(1) Based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, minus 27,866,666 shares of Common Stock purchased by the Issuer in the tender offer that was completed as of the date of this filing and 5,459,183 shares of Common Stock sold by the Funds (as defined below) to the Issuer pursuant to the Stock Purchase Agreement (as defined in Item 4) dated May 12, 2024 plus 111,414 shares of Common Stock underlying 111,414 Stock Options plus 2,505 shares of Common Stock received from vested RSUs. 

Amendment No. 31 to Schedule 13D

This Amendment No. 31 to Schedule 13D amends and supplements the statements on the previously filed Schedule 13D, as amended, filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker, Felix J. Baker, FBB2, LLC (“FBB2”), FBB3 LLC (“FBB3”) and FBB Associates (“FBB”). Except as supplemented herein, such statements, as hereto amended and supplemented, remain in full force and effect. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D, as amended.

The Adviser GP is the sole general partner of the Adviser. Pursuant to management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”), and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

Item 4. Purpose of the Transaction.

Item 4 of Amendment No. 31 is supplemented and superseded, as the case may be, as follows:

On June 13, 2024, Incyte Corporation (the “Issuer”) announced the results of its modified “Dutch auction” tender offer (the “Tender Offer”) to purchase shares of its Common Stock. The Issuer announced that, in accordance with the terms and conditions of the Tender Offer, it expects to purchase 27,866,666 million shares of its Common Stock through the Tender Offer at a purchase price of $60.00 per share.  Based on these results and pursuant to the terms of the Stock Purchase Agreement dated May 12, 2024 between the Issuer, discussed in detail in an earlier amendment to this Schedule 13D, the Funds, FBB, FBB2, FBB3, Felix J. Baker, and Julian C. Baker (“the Stock Purchase Agreement”), the Funds sold, in aggregate, 5,459,183 shares of Common Stock to the Issuer at a purchase price of $60.00 per share, for aggregate total proceeds to the Funds of $327,550,980. Of these aggregate amounts, Life Sciences sold 5,283,206 shares of Common Stock to the Issuer, for proceeds of $316,992,360, and 667 sold 175,977 shares of Common Stock to the Issuer, for proceeds of $10,558,620, in each case subject to the terms of the Stock Purchase Agreement. The sale of Common Stock pursuant to the Stock Purchase Agreement is expected to close on or about June 26, 2024.

The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities of the Issuer or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the “Board”) and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer’s management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may make suggestions to the management of the Issuer regarding financing, and may acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of some or all of the Stock Options (as defined in Item 5), vesting of restricted stock units (each an “RSU”) or otherwise) or may dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control.

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5 of this Amendment No. 31 is amended and restated as follows:

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 31 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of the Funds and the percentage of the Issuer’s outstanding shares of Common Stock such holdings represent. The information set forth below is based on 224,877,348 shares of Common Stock outstanding as of June 7, 2024, as obtained from the Issuer on June 12, 2024, less 27,866,666 shares of Common Stock purchased by the Issuer in the Tender Offer that was completed as of the date of this filing, less 5,459,183 shares of Common Stock sold by the Funds to the Issuer pursuant to the Stock Purchase Agreement ,plus 111,414 shares of Common Stock underlying 111,414 Stock Options, plus 2,505 shares of Common Stock received from vested RSUs. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

The Adviser GP, Felix J. Baker and Julian C. Baker, as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

Julian C. Baker and Felix J. Baker are also the sole managers of FBB2 and FBB3 and by policy they do not transact in or vote the securities of the Issuer held by FBB2 and FBB3.

Julian C. Baker and Felix J. Baker are also the sole partners of FBB and as such may be deemed to be beneficial owners of securities owned by FBB and may be deemed to have the power to vote or direct the vote and dispose or direct the disposition of those securities.

On June 12, 2024, the Issuer granted Julian C. Baker 12,517 Stock Options (as defined below) pursuant to the Issuer’s Restated 2010 Stock Incentive Plan (the "Incentive Plan") at an exercise price of $59.94 which vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholders of the Issuer, or a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on the Board through the vesting date. The Stock Options expire on June 11, 2034. Additionally, on June 12, 2024, the Issuer granted Julian C. Baker 2,830 RSUs. The RSUs fully vest on the earlier of June 12, 2025, the date of the next annual meeting of stockholder’s of the Issuer or upon a change in control as defined in the Incentive Plan, subject to Julian C. Baker's continuous service on Board through the vesting date.

In connection with his service on the Issuer’s Board, Julian C. Baker holds options to purchase Common Stock of the Issuer (“Stock Options”), RSUs, Common Stock and Common Stock received from the exercise of Stock Options as disclosed in previous amendments to this Schedule 13D.

Julian C. Baker serves on the Board as a representative of the Funds. The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as a director of the Issuer. Therefore, Julian C. Baker has no pecuniary interest in the Stock Options, Common Stock, RSUs or Common Stock received from the exercise of Stock Options or vesting of RSUs received as directors’ compensation. The Funds are instead entitled to the pecuniary interest in the Stock Options, Common Stock, RSUs and Common Stock received from the exercise of Stock Options and vesting of RSUs received as directors’ compensation.

The Adviser has voting and investment power over the Stock Options, RSUs, Common Stock and Common Stock underlying such Stock Options and Common Stock received from the exercise of Stock Options by Julian C. Baker received as directors’ compensation. The Adviser GP, and Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of the Stock Options, RSUs, Common Stock, Common Stock received from the exercise of Stock Options and Common Stock underlying such Stock Options held by Julian C. Baker received as director’s compensation.

(c) Except as disclosed herein or in any previous amendments to this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer.

Item 6 of this Schedule 13D is hereby supplemented and amended, as the case may be, as follows:

The disclosure in Item 4 is incorporated by reference herein.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 14, 2024